PFE vs GILD vs BMY
161 measures in 16 categories, one definition each, computed from filings and market data.
PFE46.1
Pfizer Inc.
Healthcare · Drug Manufacturers - General
$29.58 +0.44%$168.6B mkt cap
Score DNA
GILD43.8
Gilead Sciences, Inc.
Healthcare · Drug Manufacturers - General
$156.19 −0.75%$193.7B mkt cap
Score DNA
BMY67.7
Bristol-Myers Squibb Company
Healthcare · Drug Manufacturers - General
$59.75 −1.35%$122.1B mkt cap
Score DNA
Price, rebased to 100 three years ago
PFE GILD BMY · weekly adjusted closesSmart money 8Valuation 16Profitability (TTM) 12Returns on capital 11Growth 17Margin history & stability 7Liquidity (latest quarter) 7Leverage & solvency (latest quarter) 13Efficiency 11Cash flow & earnings quality 7Dividends & buybacks 9Scores & forensic checks 15Per share 7Size (TTM) 8Price performance 9Technicals 4
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.
Smart money
8 measures| Measure | PFE | GILD | BMY |
|---|---|---|---|
| Insider open-market buys, 180d | 3 | 0 | 0 |
| Insider $ bought, 180d | $2.96M | — | — |
| Congress purchases, 180d | 3 | 5 | 0 |
| Last Congress purchase | 2026-09-25 | 2026-05-06 | — |
| 13F net change in holders | −119 | −32 | −11 |
| ETFs adding shares, 30d | 1,403 | 1,962 | 1,731 |
| ETFs trimming, 30d | 1,166 | 1,592 | 1,312 |
| Net ETF funds, 30d | +237 | +370 | +419 |
Valuation
16 measures| Measure | PFE | GILD | BMY |
|---|---|---|---|
| P/E (TTM) | 38.9x
60th
|
— | 13.2x
0th
|
| PEG (P/E ÷ 3-yr EPS CAGR) | — | — | 2.14
80th
|
| Price / sales | 2.6x
18th
|
6.4x
82nd
|
2.5x
9th
|
| Price / book | 2.0x
10th
|
16.4x
80th
|
5.5x
40th
|
| Price / tangible book | — | — | — |
| Price / free cash flow | 15.3x
36th
|
14.7x
27th
|
10.7x
9th
|
| Price / operating cash flow | 12.6x
27th
|
14.3x
36th
|
9.5x
9th
|
| Enterprise value | $220.1B
36th
|
$216.7B
27th
|
$154.1B
18th
|
| EV / sales | 3.5x
18th
|
7.1x
73rd
|
3.1x
9th
|
| EV / EBITDA | 16.9x
45th
|
162.5x
100th
|
9.6x
9th
|
| EV / EBIT | 31.9x
60th
|
— | 11.8x
10th
|
| EV / free cash flow | 20.0x
27th
|
16.4x
18th
|
13.5x
0th
|
| Earnings yield | 2.6%
45th
|
-1.7%
0th
|
7.6%
100th
|
| FCF yield | 6.5%
64th
|
6.8%
73rd
|
9.4%
91st
|
| Operating cash flow yield | 7.9%
73rd
|
7.0%
64th
|
10.5%
91st
|
| Graham number (per share) | $15.99
11th
|
— | $33.33
33rd
|
Profitability (TTM)
12 measures| Measure | PFE | GILD | BMY |
|---|---|---|---|
| Gross margin | 71.3%
36th
|
79.6%
91st
|
70.2%
27th
|
| EBITDA margin | 20.5%
9th
|
4.4%
0th
|
32.8%
45th
|
| Operating margin | 25.1%
45th
|
-4.9%
0th
|
25.3%
55th
|
| EBIT margin | 10.8%
9th
|
-4.7%
0th
|
26.6%
73rd
|
| Net margin | 6.8%
27th
|
-10.6%
0th
|
18.9%
64th
|
| NOPAT margin | 26.1%
82nd
|
-3.9%
0th
|
19.7%
45th
|
| FCF margin | 17.2%
18th
|
43.3%
100th
|
23.3%
36th
|
| Operating cash flow margin | 21.0%
9th
|
44.5%
100th
|
26.0%
36th
|
| R&D / revenue | 20.1%
64th
|
19.9%
45th
|
21.8%
82nd
|
| SG&A / revenue | 20.9%
36th
|
21.2%
45th
|
15.1%
0th
|
| Stock comp / revenue | 1.1%
64th
|
1.5%
91st
|
1.1%
55th
|
| Effective tax rate | -3.9%
0th
|
21.0%
64th
|
22.1%
73rd
|
Returns on capital
11 measures| Measure | PFE | GILD | BMY |
|---|---|---|---|
| ROE (on average equity) | 5.0%
20th
|
-20.6%
0th
|
46.7%
80th
|
| ROA | 2.1%
18th
|
-6.2%
0th
|
10.2%
73rd
|
| ROIC | 12.1%
36th
|
-3.4%
0th
|
17.8%
64th
|
| ROCE | 4.1%
18th
|
-3.7%
0th
|
19.0%
91st
|
| Return on tangible assets | 3.4%
9th
|
-2.7%
0th
|
14.4%
82nd
|
| Cash ROIC (OCF / invested capital) | 9.8%
9th
|
38.8%
100th
|
23.5%
73rd
|
| Gross profitability (GP / assets) | 22.6%
9th
|
49.1%
100th
|
39.4%
73rd
|
| ROIC, 3-yr average | 5.9%
36th
|
3.5%
0th
|
5.0%
18th
|
| ROIC, 5-yr average | 12.1%
44th
|
6.9%
0th
|
7.1%
11th
|
| ROE, 5-yr average | 13.9%
33rd
|
11.4%
11th
|
15.5%
44th
|
| Incremental ROIC | -257.4%
9th
|
94.2%
82nd
|
-197.0%
27th
|
Growth
17 measures| Measure | PFE | GILD | BMY |
|---|---|---|---|
| Revenue growth (TTM YoY) | -0.2%
18th
|
5.5%
55th
|
3.1%
36th
|
| Revenue growth (QoQ) | 4.0%
18th
|
12.1%
64th
|
12.9%
73rd
|
| Revenue CAGR, 3 yr | -6.7%
0th
|
3.6%
36th
|
2.9%
27th
|
| Revenue CAGR, 5 yr | 2.9%
45th
|
2.7%
36th
|
2.1%
27th
|
| Gross profit CAGR, 3 yr | -3.1%
18th
|
3.7%
27th
|
10.5%
73rd
|
| Operating income CAGR, 3 yr | -12.8%
10th
|
— | 14.3%
60th
|
| Net income growth (TTM YoY) | -59.7%
20th
|
— | 83.8%
90th
|
| Net income CAGR, 3 yr | -41.4%
0th
|
— | 5.2%
60th
|
| EPS growth (TTM YoY) | -59.6%
20th
|
— | 82.9%
80th
|
| EPS CAGR, 3 yr | -41.3%
0th
|
— | 6.2%
60th
|
| EPS CAGR, 5 yr | -19.8%
0th
|
— | — |
| FCF growth (TTM YoY) | -11.7%
10th
|
40.9%
90th
|
-21.5%
0th
|
| FCF CAGR, 3 yr | 1.0%
9th
|
13.9%
55th
|
2.2%
27th
|
| Operating cash flow CAGR, 3 yr | -2.7%
9th
|
12.5%
82nd
|
2.6%
27th
|
| Book value CAGR, 3 yr | -4.8%
22nd
|
-17.3%
0th
|
-10.5%
11th
|
| Dividend CAGR, 3 yr | 0.6%
10th
|
1.3%
20th
|
1.8%
40th
|
| Sustainable growth rate | -6.3%
11th
|
— | 21.1%
67th
|
Margin history & stability
7 measures| Measure | PFE | GILD | BMY |
|---|---|---|---|
| Gross margin, 3-yr average | 62.6%
9th
|
77.9%
82nd
|
62.7%
18th
|
| Operating margin, 3-yr average | 19.5%
18th
|
10.7%
0th
|
23.0%
45th
|
| Net margin, 3-yr average | 6.3%
18th
|
5.0%
0th
|
5.1%
9th
|
| FCF margin, 3-yr average | 15.1%
18th
|
33.5%
100th
|
27.2%
73rd
|
| Revenue stability (0-1) | 0.02
0th
|
0.88
64th
|
0.94
91st
|
| Earnings stability (0-1) | 0.33
64th
|
0.35
73rd
|
0.17
45th
|
| Margin stability (0-1) | 0.87
0th
|
0.98
91st
|
0.90
9th
|
Liquidity (latest quarter)
7 measures| Measure | PFE | GILD | BMY |
|---|---|---|---|
| Cash & short-term investments | $11.7B
82nd
|
$3.2B
18th
|
$11.1B
73rd
|
| Net cash (− = net debt) | −$51.5B
9th
|
−$23.1B
82nd
|
−$32.1B
55th
|
| Working capital | $8.7B
64th
|
$2.9B
36th
|
$9.9B
91st
|
| Current ratio | 1.27
45th
|
1.27
36th
|
1.53
82nd
|
| Quick ratio | 0.96
36th
|
1.09
55th
|
1.38
91st
|
| Cash ratio (cash + ST investments / current liabilities) | 0.36
64th
|
0.29
45th
|
0.59
100th
|
| Defensive interval (days) | 300 days
55th
|
117 days
0th
|
358 days
64th
|
Leverage & solvency (latest quarter)
13 measures| Measure | PFE | GILD | BMY |
|---|---|---|---|
| Total debt | $63.2B
91st
|
$26.2B
18th
|
$43.1B
36th
|
| Debt / equity | 0.74
30th
|
2.22
80th
|
1.93
70th
|
| Net debt / equity | 0.60
30th
|
1.95
80th
|
1.44
70th
|
| Debt / assets | 31.4%
27th
|
53.2%
82nd
|
49.2%
64th
|
| Debt / capital | 42.6%
30th
|
68.9%
80th
|
65.9%
70th
|
| Debt / EBITDA | 4.84
82nd
|
19.67
100th
|
2.68
36th
|
| Net debt / EBITDA | 3.94
82nd
|
17.29
100th
|
1.99
36th
|
| Interest coverage (EBIT / interest) | 2.6x
18th
|
−1.4x
0th
|
9.7x
73rd
|
| Cash interest coverage | 5.0x
18th
|
13.6x
73rd
|
9.5x
45th
|
| Debt payback (years of OCF) | 4.7 yrs
91st
|
1.9 yrs
0th
|
3.4 yrs
64th
|
| Liabilities / assets | 57.5%
18th
|
76.2%
73rd
|
74.5%
55th
|
| IS credit model rating | BB | BB+ | BBB+ |
| Implied credit spread (bps) | 475
73rd
|
400
64th
|
225
45th
|
Efficiency
11 measures| Measure | PFE | GILD | BMY |
|---|---|---|---|
| Asset turnover | 0.31
0th
|
0.58
91st
|
0.54
82nd
|
| Fixed asset turnover | 3.35
27th
|
5.22
82nd
|
6.31
91st
|
| Inventory turnover | 1.7
36th
|
3.3
82nd
|
5.4
100th
|
| Receivables turnover | 5.2
64th
|
6.2
100th
|
4.9
36th
|
| Days sales outstanding | 70 days
36th
|
59 days
0th
|
75 days
64th
|
| Days inventory outstanding | 216 days
64th
|
111 days
18th
|
68 days
0th
|
| Days payables outstanding | 97 days
27th
|
37 days
0th
|
119 days
55th
|
| Cash conversion cycle (days) | 189 days
82nd
|
133 days
73rd
|
24 days
27th
|
| Capex / revenue | 3.8%
30th
|
1.2%
10th
|
2.7%
20th
|
| Capex / depreciation | 0.39
20th
|
0.13
10th
|
0.45
30th
|
| Operating expense ratio | 41.5%
55th
|
213.0%
100th
|
40.3%
45th
|
Cash flow & earnings quality
7 measures| Measure | PFE | GILD | BMY |
|---|---|---|---|
| Operating cash flow / net income | 3.09
70th
|
— | 1.38
30th
|
| FCF / net income | 2.53
70th
|
— | 1.23
40th
|
| FCF / operating cash flow | 82.0%
60th
|
97.4%
90th
|
89.5%
80th
|
| Capex / operating cash flow | 18.0%
40th
|
2.6%
10th
|
10.5%
20th
|
| Accruals ratio | -4.5%
45th
|
-32.0%
0th
|
-3.8%
73rd
|
| Sloan accruals ratio | -1.7%
55th
|
-6.4%
18th
|
1.3%
82nd
|
| Earnings quality score (0-1) | 1.00
30th
|
— | 1.00
30th
|
Scores & forensic checks
15 measures| Measure | PFE | GILD | BMY |
|---|---|---|---|
| IS score | 46
18th
|
44
9th
|
68
82nd
|
| IS profitability | 45
27th
|
20
0th
|
89
82nd
|
| IS growth | 20
9th
|
37
36th
|
63
64th
|
| IS value | 49
82nd
|
27
0th
|
67
100th
|
| IS momentum | 55
27th
|
38
0th
|
87
64th
|
| IS risk (safety) | 50
9th
|
80
55th
|
65
36th
|
| IS quality | 73
55th
|
32
0th
|
80
73rd
|
| IS balance sheet | 43
36th
|
20
0th
|
53
64th
|
| IS earnings quality | 71
82nd
|
26
0th
|
71
73rd
|
| IS cash flow | 59
9th
|
78
91st
|
62
18th
|
| Piotroski F-score (0-9) | 7
45th
|
5
18th
|
8
73rd
|
| Altman Z-score | 2.0
9th
|
3.2
55th
|
2.6
36th
|
| Beneish M-score | −2.72
45th
|
−4.14
0th
|
−2.98
9th
|
| Ohlson O-score | −8.49
27th
|
−6.75
91st
|
−7.96
55th
|
| IS credit score | 43
18th
|
47
36th
|
63
55th
|
Size (TTM)
8 measures| Measure | PFE | GILD | BMY |
|---|---|---|---|
| Market cap | $168.6B
27th
|
$193.7B
36th
|
$122.1B
18th
|
| Revenue | $63.7B
64th
|
$30.5B
18th
|
$49.2B
36th
|
| EBITDA | $13.1B
27th
|
$1.3B
9th
|
$16.1B
45th
|
| Net income | $4.3B
36th
|
−$3.2B
0th
|
$9.3B
64th
|
| Free cash flow | $11.0B
36th
|
$13.2B
55th
|
$11.4B
45th
|
| Total assets | $201.1B
100th
|
$49.4B
18th
|
$87.6B
27th
|
| Shareholders' equity | $85.2B
100th
|
$11.8B
27th
|
$22.3B
45th
|
| Employees | 75,000
73rd
|
17,000
18th
|
32,500
36th
|
Price performance
9 measures| Measure | PFE | GILD | BMY |
|---|---|---|---|
| 1 day | +0.4% | −0.8% | −1.4% |
| 1 week | +4.6% | +3.3% | +1.1% |
| 1 month | +7.0% | +3.5% | −3.9% |
| 3 months | +21.6% | +17.2% | +0.3% |
| 6 months | +7.3% | +13.5% | +1.5% |
| Year to date | +19.4% | +28.4% | +15.4% |
| 1 year | +23.4% | +32.9% | +43.1% |
| 3 years, cumulative | +3.0% | +119.2% | +21.5% |
| 5 years, cumulative | −13.7% | +169.4% | +28.4% |
Technicals
4 measures| Measure | PFE | GILD | BMY |
|---|---|---|---|
| RSI 14 | 69.7 | 63.5 | 45.5 |
| From 52-week high | −1.0% | −2.7% | −12.1% |
| From 52-week low | +25.2% | +37.9% | +46.8% |
| Beta | 0.28 | 0.33 | 0.23 |
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17